Cancers | VOL. 14
Read

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.

Publication Date Sep 5, 2022

Abstract

Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors (PARPi) are approved for BRCA1/2 carriers with HER2-negative breast cancer in the adjuvant setting with a high risk of recurrence as well as the metastatic setting. However, the indications for PARPi are broader for patients with other cancer types (e.g., prostate and ovarian cancer), involving additional biomarkers (e.g., ATM, PALB2, and CHEK) and genomic instability scores. Herein, we summarize the data on PARPi and breast cancer and discuss their use beyond BRCA carriers.

Concepts

Poly-adenosine Diphosphate Ribose Polymerase ) Inhibitors Poly-adenosine Diphosphate Ribose Polymerase High Risk Of Recurrence HER2-negative Breast Cancer BRCA Carriers Breast Cancer Metastatic Setting Adjuvant Setting Ribose Polymerase Inhibitors Ovarian Cancer

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Climate change Research Articles published between Nov 21, 2022 to Nov 27, 2022

R DiscoveryNov 28, 2022
R DiscoveryArticles Included:  2

No potential conflict of interest was reported by the authors. The conception and design of the study, acquisition of data, analysis and interpretatio...

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19

ONE PROBLEM . ONE PURPOSE . ONE PLACE

Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.